Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.incyte.com
Incyte Corporation News Releases
Get the latest updates from Incyte Corporation News Releases directly as they happen.
Follow now 178 followers
Latest posts
Last updated 3 months ago
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
3 months ago
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable...
Incyte Announces Executive Leadership Appointments
3 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Mar. 25, 2026-- Incyte (NASDAQ:INCY) today announced appointments among...
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
3 months ago
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 &amp...
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
3 months ago
- Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy)...
Incyte to Present at Upcoming Investor Conferences
4 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Feb. 17, 2026-- Incyte (Nasdaq:INCY) announced today that it...
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
4 months ago
Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025...
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
5 months ago
Pending the European Commission decision, Zynyz ® (retifanlimab) in combination with carboplatin...
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
5 months ago
Pending the European Commission decision, Zynyz ® (retifanlimab) in combination with carboplatin...
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
5 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jan. 27, 2026-- Incyte (Nasdaq:INCY) announced today that it...
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
5 months ago
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
6 months ago
TOKYO --(BUSINESS WIRE)--Dec. 22, 2025-- Incyte Biosciences Japan G.K. today announced approval...
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
6 months ago
TOKYO --(BUSINESS WIRE)--Dec. 22, 2025-- Incyte Biosciences Japan G.K. today announced the...